Appointments

Vect-Horus, a private biotechnology company specialising in molecular development, has announced the appointment of Jérôme Berger to its board of directors.

Mr Berger brings experience from his previous role at Orange Group as president and managing partner. From this role, he garnered experience by overseeing investments in technology start-ups. As global head of financing and treasury, Mr Berger was responsible for funding operations, managing equity and debt markets and leading infrastructure financing initiatives, including but not limited to the execution of several international, multibillion dollar mergers and acquisitions. He currently serves as global head of Strategy and Venture Capital at Orange Group.

Alexandre Tokay, co-founder and CEO of Vect-Horus stated: “We are thrilled to welcome Jérôme Berger to our board of directors, as Vect-Horus is poised to enter its next phase of growth. Jérôme’s unparalleled experience in strategy, venture capital and global financing, coupled with his strong background in digital health and life sciences, will be invaluable in supporting the development of Vect-Horus as we aim to revolutionise targeted drug delivery.”

Mr Berger has over two decades of experience in the life sciences industry, which Vect-Horus believe will be invaluable in steering the company towards faster growth and development. Mr Berger has previously served as the director for several other biotech companies including Future4Care which was co-founded by Mr Berger during his time at Orange Group in collaboration with Sanofi, Generali and Capgemini.